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An Interview With Commissioner Mark B. McClellan, 
U.S. Food and Drug Administration 
Judyth Pendell 
 
Q:  Let me start with a general question: How would you describe the proper 
role of the tort system, and how does it fall short of how it ought to be working? 
  
A:  That's a very big question.  The tort system potentially has a very important role 
to play in assuring the safety of products.  As you may know, I come by that knowledge 
by osmosis.  My grandfather wrote one of the major torts textbooks: Prosser and Keaton 
On Torts.  He was Keaton.  So, I grew up understanding that a key principle of tort law is 
that the party you hold liable for damages should be the party most able to prevent the 
harm.  In principle this creates the right incentives for preventing injuries, in those 
circumstances where the product developer can take steps to prevent them.  
  That only works well, though, when we have a good system in place that is 
capable of determining causation and negligence.  Unfortunately, in too many cases 
involving liability in healthcare, the system, clearly isn't succeeding at this challenge. 
  There's an overwhelming amount of evidence, mainly from studies of physicians, 
that shows that very often compensation is paid in cases where the outcomes are bad, but 
the patients have not been negligently injured.  Those who do get compensation are 
paying a very high administrative load to get there.  Most of the money doesn't go to the 
patients, who become caught up in a very long and costly dilatory system.   
  It doesn't work much better when it comes to medical products.  We've seen a 
number of cases where mass tort actions are based on FDA warnings.  So, somebody's 
reading the product labels.  We want the patients to do it not the trial lawyers, though.  
When we put a new warning on a product that generally means that we found some new 
evidence to lead us to a new conclusion about a newly identified risk associated with a 
product.  It doesn't necessarily or generally mean that the product developer missed a 
problem that they should have known about.  That’s what the courts need to do a better 
job of distinguishing. 
  We have a very comprehensive regulatory system for medical products at the 
FDA.  When we get the information that our regulatory system asks for, and get it in a   2  
timely way, we can provide fairly comprehensive interpretations of what the latest 
evidence has to say about risks and benefits of products.  
  That's true for new products coming on the market where product developers have 
to submit a comprehensive set of information on safety and effectiveness.  And if they 
withhold anything, that's something they're legally liable for.  And there should be 
penalties attached, including the tort system.   
  It's also true when new information is developed after a product is on the market.  
The product developers are responsible for complying with our regulations on reporting 
when they have any new information on adverse events or new causes for concern.  And, 
we need to take further action based on that information. If the product developers don't 
provide that information, then they should be penalized. But, when they're fully 
compliant in cases where something new is learned through real-world experience, and 
then it is reported to us, the system should acknowledge the role they played in patient 
safety and act in ways that encourage them to be aggressive about ongoing testing in the 
future and diligent in reporting results to us.  
 
Q:  What impact, if any, does tort litigation have on research and development in 
the pharmaceutical industry? 
  
A:  I think the tort system has been an important deterrent to the development of new 
products in such areas as reproductive therapies; birth control therapies; treatments 
during pregnancy, and the like, where we've seen very little innovation over the last few 
decades.   
  It's a potentially important factor in deterring the development of better 
medications needed in other areas, especially where patients can suffer serious adverse 
outcomes, not because of the product but because of the nature of their disease.  If the tort 
system doesn't do a good job of distinguishing between the consequences of the product 
use versus bad outcomes attributable to the patient’s disease, you can see how there 
would be a big over-deterrent effect.  The tort system is just not doing a very good job in 
that area. 
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Q:  Innovation seems to be in a slump.  I understand that applications for 
approvals are significantly down from where they would be expected to be.  What 
role, if any, has the tort system played?  
 
A:  There are many factors responsible and I think that the main factor across the 
board is probably not liability.  But liability is an important consideration, especially in 
certain product areas. 
  One important thing that is happening is that we're seeing a transition in the way 
that medical products are developed from an old style where, by understanding a 
particular receptor in the body, companies would synthesize a new molecule that could be 
the basis for a blockbuster drug.  Today, research is going into new kinds of areas:   
genomics, where you can get a solid understanding of the genetic and then the cellular 
basis for diseases in individual patients, and nanotechnology, where we can make devices 
that do a much better job of getting the right treatment to the right place in the body at the 
right time.  It's a different way of developing products.  Historically, it's taken a long time 
and cost a lot of money for new ways of providing medical therapies to reach patients.  It 
can take a decade or longer to develop a new drug. So, there are a lot of reasons for the 
slow down.  But I think liability costs are an important contributing factor and in some 
areas--like treatments during pregnancy and like some forms of birth control, for 
example, we just haven't seen very many products developed at all…not just in the last 
few years, when this slow down has occurred, but in the last two decades. 
  In the area of pregnancy treatments, there have been, really, no new products 
brought on the market and tested and labeled as safe and effective by the FDA for certain 
kinds of pregnancy symptoms such as nausea and vomiting, which can cause nutritional 
problems and dehydration, serious consequences for the mother and the baby.  We just 
haven't seen any approved innovations in those areas.  And that's a much more 
longstanding problem than the recent slow-down.   
 
Q:  Let's talk about warnings for just a minute.  In your view how does the tort 
system affect your ability to develop warnings that are meaningful to patients? 
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A:  It is a complicating factor.  We are, right now, in the process of revising our labels 
for physicians and will do the same thing for patients, as well, to make them more usable.  
We are entering a new era of information use in health care.  The amount of medical 
knowledge has just exploded in recent years.  Fortunately, there have also been some 
important improvements in our systems available for helping people use that information.  
Computerized information technology systems are good tools; they can help get the right 
information to a doctor or patient at the time when they're making a prescribing decision, 
when they're deciding about which medicine to use, or which treatment to use. 
  To incorporate information efficiently in these kinds of electronic systems the 
format should contain a brief summary set of information that is also navigable, so that 
you can click on some piece of information about an important risk or an important 
benefit or an important indication for a specific type of patient and then receive more 
detailed information.  We need to start with the brief summary so that the physician can 
become oriented to what they really need to know. 
  We are trying to get such a system adopted for physician labeling.  When we 
initially made this kind of proposal, though, many of the product developers were very 
concerned that if certain warnings weren't included in the brief summary information, 
they could potentially be found liable.  The argument would go: you didn’t describe each 
and everything that might go wrong, even in rare cases, when you provided physicians 
this quick overview to get them oriented to the medicine.  The argument would be raised 
even though there were links in there for the more detailed information.  So, liability 
concerns could be a real inhibitor to getting easily navigable and useful labeling 
information out.  
  The same thing goes for warning information.  We want warnings to go on 
products when there is evidence that there is a real safety risk; not when there is a 
concern by a company's lawyer that they may get sued if an adverse event occurs.   
 
Q:  Can you give me an example of a warning driven by liability risks as opposed 
to safety risks?  
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A:  A good example is provided by some of the antidepressant drugs, where suicide is 
a known and unfortunate complication of depression. 
  Three times over the past decade, one of the antidepressant manufacturers has 
come to us to ask to put a warning about suicide on their product label.  We reviewed the 
evidence and found it not compelling.  Moreover, our scientists and clinicians were 
worried that that warning on the label would have a negative public health effect by 
deterring people from taking the medication when they were depressed.  And, since 
suicide is the most serious complication of depression that we want to prevent, three 
times we turned it down.  Yet, subsequent to that, there have been lawsuits brought 
against the company for failure to warn, saying that the information should have been on 
the label, even though FDA told the company, you can't put it on the label. 
  So, this kind of complication in getting the right science-based information on the 
label and in the warning information is something that we see on a regular basis at FDA.  
And it interferes with our ability to communicate effectively with medical professionals. 
  
Q:  Apparently, another way patients get information about safety is by reading 
about lawsuits.  I recently participated in the commissioning of a Harris Poll of 
doctors, pharmacists, and patients. One of the things that we learned was patients 
might stop taking a medication if they learned the drug was involved in some 
litigation. The inference is: if someone is suing, it must be harmful.  Do you have a 
proposal for helping the courts deal more effectively with the scientific evidence in 
drug litigation? 
  
A:  I think we would appreciate it if the courts would defer to us more on the science.  
In contrast to most other areas of our economy, we have a comprehensive regulatory 
system in place when it comes to medical products. 
  No product gets on the market unless we say it's safe and effective; unless it's 
been proven to be safe and effective.  And no product can stay on the market if we think 
there are concerns that should result in its being removed, or its indications for use being 
modified, or a warning placed on the label.   6  
  It's exactly the kind of comprehensive structure that the tort system was intended 
to address.  The whole point of having a tort system in the first place is to make sure the 
manufacturer pays attention to risks not outweighing the benefits.  Well, that's what our 
entire regulatory structure at FDA is intended to do.  We don't approve a product unless 
the benefits outweigh the risks. 
  We design labeling to maximize benefits and minimize risks for patients.  All the 
other public health activities are focused exactly on that goal.  By spending a lot of time 
and effort, having a lot of scientific expertise and medical expertise to review all the 
relevant evidence and keep the product labels and product review decisions up to date 
and based on the best science, we're accomplishing much of what tort law was initially 
intended to do.  And we're doing it in a way that's based on scientific expertise and 
science resources that courts and juries simply do not have.  
 
Q:  Can you characterize the state of the law in terms of the courts upholding an 
FDA defense? 
 
A:  Some states have made it clear that an FDA defense should be a reasonable 
defense against a tort claim.  In other states, in other jurisdictions, however, we have had 
problems with judges finding in the other direction, such as in that antidepressant case 
that I mentioned before.  We are intervening in some of these cases with amicus briefs in 
order to preserve our control over the medical product labels. 
  I think it's very important for FDA and not a jury to have the ultimate say as to 
what the guidance should be for practitioners and patients when it comes to using medical 
products.  
  
Q:  I would be interested in the process that led to the recent FDA decision 
regarding breast implants.  
 
A:  This is a good example of how we want our scientific process to work.  We have 
advisory committees review the application that a company submits, along with our 
evaluation of that application and questions that we pose to this expert advisory   7  
committee, to help us make sure our decisions about that product are based on a full and 
complete evaluation of the latest scientific evidence.  
  When the advisory committee meets and issues its recommendations or its 
responses to our questions, we then take all that information, as well as all the public 
comments, back into our internal regulatory process to come to a final decision about 
product approval and the conditions under which the product would be approved--what 
kind of labeling is required; what king of further monitoring of patients; what studies will 
be needed, and so forth. 
  So, the advisory committee process that we had on the silicone breast implants is 
a good example of that process.  In that meeting, we had about 15 independent scientific 
advisors review evidence that the company presented, as well as concerns and issues that 
our scientific staff had raised. They then reached conclusions as to whether the product 
was safe and should be marketed. 
  Now, that's not a final decision.  It's really just a public airing of all of the relevant 
scientific evidence.  And the reason that's important in cases like silicone breast implants 
where there are important considerations on both sides is that we want to be sure that 
we've evaluated all the evidence and heard all the public view points when it comes to 
making our regulatory decisions.  We want to be confident when we make a final 
decision that we've heard a full range of opinions and we've looked at all the evidence.  
And that's the right process I think, for a science-based, regulatory agency to help make 
sure that people get safe and effective treatments. 
  
Q:  How important is changing the legal system or some kind of legal reform to 
achieving your major policy objectives? 
  
A:  I think some legal reforms could be very helpful.  And not just when it comes to 
medical products, but for our whole health care medical liability system more generally.  
We do not have a healthcare delivery environment that enables the sharing of information 
about medical errors that have occurred and the prevention of medical errors.  There was 
an attempt to pass legislation this year that would have provided protections for doctors 
and healthcare organizations who work together to talk about medical errors, review   8  
errors that have occurred, discuss errors just barely averted, and consider steps that 
should be take to prevent errors in the future.  The legislation would not have made 
medical records and other traditional sources of information for lawsuits “off limits” to 
trial lawyers.  The bill did not make it through the Congress.  It’s too bad because that 
legislation would have really provided a focused and much needed mechanism for 
developing information that could prevent errors, creating an environment that 
encourages practices that are safe and effective and don't put patients at risk.  Too often, 
our doctors feel like they're on their own when it comes to managing errors and 
preventing errors.  In a very complicated healthcare system, like the one we have today, 
that's not the most effective way to go. 
  
Q:  Are other countries doing it better or differently?  
 
A:  I'm not as much an expert on what's going on in other countries as I should be.  
There are two factors that are, broadly speaking, different in other countries.  One is that 
the liability pressures are just not as high.  There are not as many lawsuits brought and it's 
not as much in the forefront of healthcare providers’ minds as it is in the United States. 
  Second, many other countries do not handle these kinds of questions of provider 
negligence through jury trials. In some cases they have specialized courts of one kind of 
another with some real medical expertise to review and make decisions.  For both of 
those reasons, liability costs are lower and you don't see the same kinds of pressures for 
defensive medical practices or the same liability impacts as in the United States. 
  So, there may well be some models there.  But I also think there's a model in what 
FDA does for medical products.  I mean we've got a very science-based, comprehensive 
system for regulating the safety and effectiveness of medical products.  As long as we 
have the data and the information and support we need to do our job effectively, we can 
do a pretty good job of making sure the products on the market are safe.  We can help 
doctors and other practitioners to identify problems where they exist and take steps to 
prevent them.  It's not a bad model for ensuring patient safety. 
  